Hyperprogression of cutaneous T cell lymphoma after anti-PD-1 treatment

• Published in: JCI insight 2023-02, Vol.8 (4)
• Main Authors: Gao, Yumei, Hu, Simeng, Li, Ruoyan, Jin, Shanzhao, Liu, Fengjie, Liu, Xiangjun, Li, Yingyi, Yan, Yicen, Liu, Weiping, Gong, Jifang, Yang, Shuxia, Tu, Ping, Shen, Lin, Bai, Fan, Wang, Yang
• Format: Article
• Language: English
• Subjects: Adolescent; Clinical Medicine; Humans; Lymphoma, T-Cell, Cutaneous; Oncology; Protein Kinase C-theta; Receptors, Antigen, T-Cell; Signal Transduction; Skin Neoplasms
• ISSN: 2379-3708; 2379-3708
• DOI: 10.1172/jci.insight.164793

BACKGROUNDImmune checkpoint blockade is an emerging treatment for T cell non-Hodgkin's lymphoma (T-NHL), but some patients with T-NHL have experienced hyperprogression with undetermined mechanisms upon anti-PD-1 therapy.METHODSSingle-cell RNA-Seq, whole-genome sequencing, whole-exome sequencing, and functional assays were performed on primary malignant T cells from a patient with advanced cutaneous T cell lymphoma who experienced hyperprogression upon anti-PD-1 treatment.RESULTSThe patient was enrolled in a clinical trial of anti-PD-1 therapy and experienced disease hyperprogression. Single-cell RNA-Seq revealed that PD-1 blockade elicited a remarkable activation and proliferation of the CD4+ malignant T cells, which showed functional PD-1 expression and an exhausted status. Further analyses identified somatic amplification of PRKCQ in the malignant T cells. PRKCQ encodes PKCθ; PKCθ is a key player in the T cell activation/NF-κB pathway. PRKCQ amplification led to high expressions of PKCθ and p-PKCθ (T538) on the malignant T cells, resulting in an oncogenic activation of the T cell receptor (TCR) signaling pathway. PD-1 blockade in this patient released this signaling, derepressed the proliferation of malignant T cells, and resulted in disease hyperprogression.CONCLUSIONOur study provides real-world clinical evidence that PD-1 acts as a tumor suppressor for malignant T cells with oncogenic TCR activation.TRIAL REGISTRATIONClinicalTrials.gov (NCT03809767).FUNDINGThe National Natural Science Foundation of China (81922058), the National Science Fund for Distinguished Young Scholars (T2125002), the National Science and Technology Major Project (2019YFC1315702), the National Youth Top-Notch Talent Support Program (283812), and the Peking University Clinical Medicine plus X Youth Project (PKU2019LCXQ012) supported this work.